United Asset Strategies Inc. Has $13.13 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

United Asset Strategies Inc. grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,652 shares of the company’s stock after buying an additional 444 shares during the quarter. IDEXX Laboratories makes up 1.5% of United Asset Strategies Inc.’s portfolio, making the stock its 19th largest position. United Asset Strategies Inc.’s holdings in IDEXX Laboratories were worth $13,128,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. Gotham Asset Management LLC boosted its holdings in IDEXX Laboratories by 79.9% in the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after acquiring an additional 7,741 shares during the last quarter. NewEdge Wealth LLC boosted its holdings in IDEXX Laboratories by 30.4% in the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after acquiring an additional 149 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in IDEXX Laboratories by 25.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock valued at $24,196,000 after acquiring an additional 8,831 shares during the last quarter. Carderock Capital Management Inc. boosted its holdings in IDEXX Laboratories by 35.7% in the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock valued at $9,112,000 after acquiring an additional 4,315 shares during the last quarter. Finally, Mitchell Capital Management Co. boosted its holdings in IDEXX Laboratories by 1.3% in the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after acquiring an additional 79 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on IDXX shares. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Barclays raised their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group raised their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a report on Tuesday, January 30th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $591.50.

Insider Transactions at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock valued at $24,871,960 over the last 90 days. 2.18% of the stock is owned by company insiders.

IDEXX Laboratories Stock Up 0.4 %

Shares of NASDAQ IDXX traded up $1.95 during mid-day trading on Tuesday, reaching $493.24. 212,458 shares of the company’s stock were exchanged, compared to its average volume of 421,324. The firm has a market capitalization of $40.96 billion, a price-to-earnings ratio of 48.79, a PEG ratio of 3.83 and a beta of 1.26. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $545.29 and a 200 day simple moving average of $508.55. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 earnings per share. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.